Table V.
Mean Reduction in SBP and DBP With the Maximal Tested Dose of Each ARB, as Monotherapy and in Combination With HCTZ 12.5 mg and 25 mg
| Mean Change in BP (mm Hg) | |||
|---|---|---|---|
| ARB Alone | ARB + HCTZ 12.5 mg | ARB + HCTZ 25 mg | |
| Irbesartan 300 mg 22 | |||
| SBP: absolute (placebo corrected) | −14.9 (‐12.6) | −15.9 (‐13.6) | −23.1 (‐20.8) |
| DBP: absolute (placebo corrected) | −10.2 (‐6.7) | −15.0 (‐11.5) | −14.4 (‐10.9) |
| Olmesartan 40 mg 23 | |||
| SBP: absolute (placebo corrected) | −16.0 (‐12.7) | −20.6 (‐17.3) | −26.8 (‐23.5) |
| DBP: absolute (placebo corrected) | −14.6 (‐6.4) | −17.3 (‐9.1) | −21.9 (‐13.7) |
| Telmisartan 80 mg*24 | |||
| SBP: absolute (placebo corrected) | −15.4 (‐12.5) | −23.9 (‐21.0) | N/A |
| DBP: absolute (placebo corrected) | −11.5 (‐7.7) | −14.9 (‐11.1) | N/A |
| Valsartan 160 mg 25 , 41 | |||
| SBP: absolute (placebo corrected) | −12.1 (‐10.2) | −17.7 (‐15.8) | −22.4 (‐20.5) |
| DBP: absolute (placebo corrected) | −9.4 (‐5.3) | −13.5 (‐9.4) | −15.3 (‐11.2) |
| SBP=systolic blood pressure; DBP=diastolic blood pressure; ARB=angiotensin receptor blocker; HCTZ=hydrochlorothiazide; BP=blood pressure; /N/A=not analyzed or presented in the published report; *the telmisartan study used supine BP measurements and the other studies used sitting BP measurements | |||